Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1997-1-23
|
| pubmed:abstractText |
Two yeast recombinant vaccines were compared: the Russian hepatitis B Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.). Both agents were found safe and low reactogenic. After a course of 3 vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinated after the 0-1-2 months and 0-1-6 months protocols had high levels of specific antibodies. In the group vaccinated with the American vaccine, antibodies to HBsAg were found in the sera of 95 to 100% subjects. These results demonstrate high immunological activity of both Russian and American vaccines.
|
| pubmed:language |
rus
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0507-4088
|
| pubmed:author |
pubmed-author:Bel'chenkoA VAV,
pubmed-author:BeliakovaE AEA,
pubmed-author:BorisovaV NVN,
pubmed-author:BudanovM VMV,
pubmed-author:GorbunovM AMA,
pubmed-author:IakovlevaI MIM,
pubmed-author:KorovinIu PIuP,
pubmed-author:Krasil'nikovI VIV,
pubmed-author:Lytsar'B NBN,
pubmed-author:NoskovaA VAV,
pubmed-author:PavlovaL ILI,
pubmed-author:SkvortsovS VSV,
pubmed-author:TitovI AIA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
170-2
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:articleTitle |
[Russian recombinant vaccine against hepatitis B (results of controlled trials)].
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Randomized Controlled Trial
|